Clinical trials are no longer about hard clinical endpoints. Payers are increasingly demanding patient-centered outcomes as a prerequisite to approve access to new medicines. Once regarded as ‘nice to have’ measures, PROs are increasingly seen as essential tools.
eyeforpharma’s latest whitepaper provides an in-depth analysis of PROs across research, regulation and the real-world, and looks to a future where patient engagement is the start point for clinical development, not just an endpoint.
Read the full whitepaper here - http://bit.ly/2LcP6aR
Leaders from Sanofi, Novartis, Celgene, GSK, Takeda and others discuss:
• Why patient insights are the blueprint for effective PRO design
• How effective are PROs in securing patient access?
• PROs: The future of clinical trials?
Download your copy for free here - http://bit.ly/2LcP6aR
Enjoy!